Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SELLAS Life Sciences (SLS) Change in Accured Expenses (2019 - 2024)

SELLAS Life Sciences (SLS) has disclosed Change in Accured Expenses for 9 consecutive years, with -$24000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Change in Accured Expenses fell 102.98% to -$24000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was -$2.2 million, a 250.72% decrease, with the full-year FY2024 number at -$2.2 million, down 250.72% from a year prior.
  • Change in Accured Expenses was -$24000.0 for Q4 2024 at SELLAS Life Sciences, down from $307000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $1.7 million in Q4 2022 to a low of -$1.4 million in Q2 2024.
  • A 5-year average of $219000.0 and a median of $205500.0 in 2022 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: skyrocketed 2713.11% in 2022, then plummeted 631.63% in 2024.
  • SELLAS Life Sciences' Change in Accured Expenses stood at -$391000.0 in 2020, then soared by 115.6% to $61000.0 in 2021, then surged by 2713.11% to $1.7 million in 2022, then crashed by 53.03% to $806000.0 in 2023, then crashed by 102.98% to -$24000.0 in 2024.
  • Per Business Quant, the three most recent readings for SLS's Change in Accured Expenses are -$24000.0 (Q4 2024), $307000.0 (Q3 2024), and -$1.4 million (Q2 2024).